A Randomized Controlled Trial of Topical Cannabidiol for the Treatment of Thumb Basal Joint Arthritis

Heineman, John T.; Forster, Grace L.; Stephens, Kristen L.; Cottler, Patrick S.; Timko, Michael P.; DeGeorge, Brent R.

doi:10.1016/j.jhsa.2022.03.002

Cited by 33 publications

(22 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Shreds of literature have reported that CBD promotes the osteogenic differentiation of MSCs from different sources including DPSC (34,37,38). Some clinical studies have shown that CBD promotes the healing of non-infectious arthritis (39) and exerts a bene cial effect on bone metabolism (40). In the present study, we found that CBD at a concentration of 0.1-2.5 µM did not inhibit the viability of DPSC but at a concentration of 12.5 µM dramatically inhibited the viability of DPSC.…”

Section: Discussionsupporting

confidence: 46%

Dental pulp stem cells-derived cannabidiol-pretreated micro-spheroids showed robust osteogenic potential via upregulation of WNT6

Liu

et al. 2023

Preprint

View full text Add to dashboard Cite

Dental pulp stem cells (DPSC)-derived 3D-aggregates/spheroids have shown robust soft/hard tissue regeneration potential. However, difficulties to control the cell number, size, and shape of DPSC-aggregates/spheroids cause cell necrosis and difficulties in homogenous seeding of aggregates/spheroids in the 3D-printed microporous bone grafts. Moreover, inducing the osteogenic potential of these aggregates/spheroids is still a challenge. This study developed cannabidiol (CBD)-pretreated, self-assembled, and injectable DPSC-derived osteogenic micro-spheroids (70 μm) that robustly promoted in situ bone regeneration. We developed micro-spheroids by seeding 250 cells/microwell in agarose gel microwells of 200 µm diameter developed using prefabricated mold and cultured with CBD for 14 days to induce osteogenic potential. In vitro study results showed that CBD did not affect the viability of DPSC but promoted osteogenic differentiation during 2D culture. In micro-spheroids, 3D cytoskeleton visualization showed better integrity and robustly higher expression of osteogenic markers and promoted in situ bone regeneration compared with DPSC. CBD-pretreated micro-spheroids showed robustly higher bone-regenerative capacity via upregulation of WNT6. Taken together, our approach of developing organoid-like injectable osteogenic micro-spheroids can be used as the effective carrier of the effect of in vitro drug treatment during in situ bone tissue engineering which eliminates the direct in vivo drug application-related adverse effects.

show abstract

Section: Discussionsupporting

confidence: 46%

Dental pulp stem cells-derived cannabidiol-pretreated micro-spheroids showed robust osteogenic potential via upregulation of WNT6

Liu

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…There are few studies examining safety and tolerability of CBD alone for treatment of pain or disease, especially topical CBD. Topical CBD has been studied in symptomatic peripheral neuropathy of the lower extremities (Xu et al 2020 ), for thumb basal joint arthritis (Heineman et al 2022 ), and following total knee arthroplasty (Haffar et al 2022 ). Using a topical CBD oil in a randomized, double blind, placebo-controlled study of patients with symptomatic peripheral neuropathy of the lower extremities, Xu et al reported statistically significant reductions in pain domains assessed by the Neuropathic Pain Scale including intense ( p = 0.009), sharp ( p < 0.001), itchy ( p = 0.001), and cold ( p < 0.05) when compared to placebo controls (Xu et al 2020 ).…”

Section: Discussionmentioning

confidence: 99%

“…Its safety profile, lack of diversion potential, and growing prevalence of use warrant studies of the tolerability and efficacy of CBD for joint pain and other forms of chronic pain, especially in special populations and according to its most common routes of administration. Topical CBD has been studied in symptomatic peripheral neuropathy of the lower extremities (Xu et al 2020 ), for thumb basal joint arthritis (Heineman et al 2022 ), and following total knee arthroplasty (Haffar et al 2022 ), with mixed results. Studies in unique populations such as elite athletes are even more sparse.…”

Section: Introductionmentioning

confidence: 99%

Topical cannabidiol is well tolerated in individuals with a history of elite physical performance and chronic lower extremity pain

et al. 2023

View full text Add to dashboard Cite

Introduction Cannabidiol (CBD) is a potential therapeutic for pain management. Yet, there exists a dearth of studies of its tolerability and efficacy, especially in special populations. Former elite athletes are a special population both susceptible to chronic pain and also highly trained and attuned to assess medication tolerability concerns. The purpose of the present open-label pilot study was to assess the tolerability of CBD in this population. Materials and methods Retrospective analysis was conducted in deidentified data from 20 individuals who were all previously professional athletes in US/American football, track and field, or basketball, with careers ranging from 4 to 10 years. Participants received topical CBD (10 mg twice daily by controlled dispenser) for chronic pain resulting from acute lower extremity injuries. Assessments of tolerability and secondary analyses of pain, pain-related disability, and activities of daily living were collected by self-report over the 6-week study period. Data were analyzed by descriptive statistics, pairwise t-test, and linear regression. Results Seventy percent of participants completed the study. Of the individuals who completed the study, 50% reported minor adverse effects, none of which required medical attention, and 50% did not report any adverse effects. The mostly commonly reported effects were skin dryness (43% of study completers) and skin rash (21% of study completers), which rapidly resolved. There was a significant improvement in self-reported pain levels (intake mean 3.5 ± 0.29; exit mean 1.7 ± 0.23; P < 0.001) and pain-related disability, including family and home responsibilities, life support activities, occupational activities, recreational activities, self-care, sexual function, and social activities (all P < 0.001). Discussion To the best of our knowledge, this is the first study to assess CBD treatment in elite athletes, who are disproportionally susceptible to disabling injuries. Topical administration of CBD was tolerated well by this population and resulted in only minor adverse effects. As elite athletes are trained and attuned to assess their own bodies due to their professional lives, this population is likely to detect tolerability concerns. However, this study was limited to a convenience sample and self-reported data. These pilot findings warrant further study of topical CBD in randomized and controlled studies of elite athletes.

show abstract

Section: Clinical Studies On the Effect Of Phytocannabinoids On Skin ...mentioning

confidence: 99%

“…Despite the still small number of clinical trials, the possibility of therapeutic use of phytocannabinoids in skin diseases makes their participation in skin preparations has become more and more common in recent years [ 52 , 129 ]. This is also evidenced by patent applications and granted patents for the use of phytocannabinoids in medicinal preparations, e.g., in the pharmacotherapy of psoriasis by topical application of a composition containing cannabinoids, in particular CBD and CBG at a concentration of 3–20% by weight [ 24 ].…”

Section: Clinical Studies On the Effect Of Phytocannabinoids On Skin ...mentioning

confidence: 99%

Phytocannabinoids in the Pharmacotherapy of Psoriasis

Wroński¹,

Jarocka-Karpowicz

Jastrząb

et al. 2023

Molecules

View full text Add to dashboard Cite

Phytocannabinoids are naturally occurring compounds, the main source of which is Cannabis sativa L. Through direct action or interaction with G protein-coupled receptors, they affect ROS and pro-inflammatory cytokines levels and modify the effectiveness of transcription factor responsible for the biosynthesis of antioxidants which lead to oxidative stress and its consequences. Due to the modification of the redox balance and inflammation, phytocannabinoids are used in the treatment of various diseases, including autoimmune dermatoses, such as atopic dermatitis and psoriasis. Psoriasis is one of the most common dermatoses, and one of unknown etiology. A disturbed redox balance with a shift towards the oxidation leads to oxidative stress, resulting in oxidative modifications, mainly of lipids and proteins, and prolonged activation of immune cells and increased generation of pro-inflammatory cytokines, resulting in chronic inflammation. Given the biological activity of phytocannabinoids, they have become the focus of research as components of pharmacotherapy for psoriasis. Beneficial effects were shown by various representatives of phytocannabinoids, but the effect of cannabidiol (CBD) on skin cells (in vitro and ex vivo) and on blood cells from patients with psoriasis vulgaris and psoriatic arthritis has been most often evaluated in recent years.

show abstract

A Randomized Controlled Trial of Topical Cannabidiol for the Treatment of Thumb Basal Joint Arthritis

Cited by 33 publications

References 20 publications

Dental pulp stem cells-derived cannabidiol-pretreated micro-spheroids showed robust osteogenic potential via upregulation of WNT6

Dental pulp stem cells-derived cannabidiol-pretreated micro-spheroids showed robust osteogenic potential via upregulation of WNT6

Topical cannabidiol is well tolerated in individuals with a history of elite physical performance and chronic lower extremity pain

Phytocannabinoids in the Pharmacotherapy of Psoriasis

Contact Info

Product

Resources

About